BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24423287)

  • 1. Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype.
    Ellis RJ; Wang Y; Stevenson HS; Boufraqech M; Patel D; Nilubol N; Davis S; Edelman DC; Merino MJ; He M; Zhang L; Meltzer PS; Kebebew E
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E329-37. PubMed ID: 24423287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
    Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
    Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
    Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
    Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
    Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.
    Jung CK; Little MP; Lubin JH; Brenner AV; Wells SA; Sigurdson AJ; Nikiforov YE
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E276-85. PubMed ID: 24248188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
    Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
    Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
    Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
    World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.
    Adeniran AJ; Zhu Z; Gandhi M; Steward DL; Fidler JP; Giordano TJ; Biddinger PW; Nikiforov YE
    Am J Surg Pathol; 2006 Feb; 30(2):216-22. PubMed ID: 16434896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
    Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population.
    Kang DY; Kim KH; Kim JM; Kim SH; Kim JY; Baik HW; Kim YS
    Thyroid; 2007 Nov; 17(11):1031-8. PubMed ID: 17900235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.
    Hou P; Liu D; Xing M
    Endocr Relat Cancer; 2011 Dec; 18(6):687-97. PubMed ID: 21937738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
    Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
    Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.